In summary, our findings demonstrate that at least 10% increase of the CX3CR1+ subset in PB CD8+ T cells identifies patients with NSCLC responding to chemo-immunotherapy early on-treatment. This evidence concerns the gene CX3CR1 and non-small cell lung carcinoma.